Journal
CURRENT ONCOLOGY
Volume 26, Issue 2, Pages 102-107Publisher
MULTIMED INC
DOI: 10.3747/co.26.4555
Keywords
Lung cancer; costs; resource utilization; administrative data; Ontario
Categories
Funding
- Government of Ontario through the Ministry of Economic Development, Job Creation and Trade
- Canadian Cancer Society [2015-703549]
- AstraZeneca Canada Inc.
- Canada's Strategy for Patient-Oriented Research (SPOR)
- Ontario SPOR Support Unit
- Canadian Institutes of Health Research
- Government of Ontario
Ask authors/readers for more resources
Background With recent advances in the treatment of non-small-cell lung cancer (NSCLC) and current fiscal constraints within publicly funded health care systems, understanding the real-world economic effect of lung cancer management has become important. The objective of the present study was to determine the costs and resources used in the management of NSCLC cohorts in Ontario. Methods Patients diagnosed between 1 April 2010 and 31 March 2015 were identified in the Ontario Cancer Registry and linked to provincial administrative databases, capturing resources such as hospitalizations, cancer clinic visits, physician services, and systemic therapies or radiotherapy. A cost-of-illness analysis using a bottom-up approach and the GETCOST macro available at ices determined the overall total and mean costs in 2017 Canadian dollars. Resource utilization results were analyzed according to the total number of encounters per resource, the number of patients using each resource, and the number of encounters per patient. A separate cost-and-resource analysis was conducted for radiotherapy. Results The 24,729 NSCLC patients identified included 4542 with stage III unresectable disease and 10,103 with stage IV nonsquamous disease. The overall total cost for all NSCLC patients was $1.9 billion, with inpatient hospitalizations ($635.2 million), cancer clinic visits ($323.7 million), and physician services ($301.4 million) being the top cost contributors. The mean cost per patient was $76,816. The total cost of radiotherapy was $38.5 million. Conclusions Real-world costs for the management of NSCLC during the 5-year period examined were substantial, despite the fact that median survival was poor and treatment information was limited.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available